Japan Lifeline Co., Ltd.
Notice of Transfer of a Specific Subsidiary Associated with Capital Increase for US Subsidiary
Capital increase to US subsidiary JLL Med USA was executed. Increase amount: 10.0 million USD; post-increase capital: 10.4 million USD; equity ownership: 100% and classification as a wholly owned subsidiary. The impact on consolidated results for the fiscal year ending March 2027 is expected to be minimal.
Key Figures
- Capital increase amount: 10,000 thousand USD
- Capital after increase: 10,400 thousand USD
- Equity ownership: 100％
AI要約
Section Heading
This matter is a capital policy aimed at strengthening the company’s US footprint as part of mid- to long-term growth strategy to expand global sales. It involves increasing the capital of US subsidiary JLL Med USA Inc. to support agile business deployment in the US market. JLL Med USA develops and sells medical devices. Post-increase, the subsidiary is 100% owned by the company, and the subsidiary’s directors also serve as officers. The subsidiary was established on August 25, 2026.
Section 2 Heading
Looking ahead, the impact on consolidated results for the fiscal year ending March 2027 is expected to be minimal, and the aim is to enhance the group’s overall corporate value by strengthening the US market base as part of the global strategy. Note that current settlement figures have not been disclosed in the announced figures.
Japan Lifeline Co., Ltd.
Company overview · Stock price · Financial data · All IR
